StockData
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.43−0.01 (-0.69%)

Close on Nov 18, 2026Market cap $82.16MP/E –Yield –

Black Diamond Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Black Diamond Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$62.30M. For fiscal 2024 it was -$62.30M. The highest annual figure on record is -$8.53M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$62.30M–
FY2023Dec 31, 2023-$66.75M–
FY2022Dec 31, 2022-$85.27M–
FY2021Dec 31, 2021-$102.86M–
FY2020Dec 31, 2020-$52.29M–
FY2019Dec 31, 2019-$24.70M–
FY2018Dec 31, 2018-$8.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$15.06M–
Q4 FY2023Dec 31, 2023-$13.96M–
Q3 FY2023Sep 30, 2023-$18.40M–
Q2 FY2023Jun 30, 2023-$14.37M–
Q1 FY2023Mar 31, 2023-$20.03M–
Q4 FY2022Dec 31, 2022-$21.94M–
Q3 FY2022Sep 30, 2022-$16.47M–
Q2 FY2022Jun 30, 2022-$18.26M–
Q1 FY2022Mar 31, 2022-$28.61M–
Q4 FY2021Dec 31, 2021-$24.38M–
Q3 FY2021Sep 30, 2021-$27.97M–
Q2 FY2021Jun 30, 2021-$26.01M–
Q1 FY2021Mar 31, 2021-$24.50M–
Q4 FY2020Dec 31, 2020-$15.88M–
Q3 FY2020Sep 30, 2020-$11.49M–
Q2 FY2020Jun 30, 2020-$13.59M–
Q1 FY2020Mar 31, 2020-$11.32M–
Q4 FY2019Dec 31, 2019-$7.49M–
Q3 FY2019Sep 30, 2019-$5.32M–
Q2 FY2019Jun 30, 2019-$5.00M–
Q1 FY2019Mar 31, 2019-$6.89M–

More Black Diamond Therapeutics figures

See a number that looks wrong?